ProcuraAxisBeta
Sign inCreate Free Account
Home / Opportunities / Opportunity
PROCUREMENT OPPORTUNITY

RMH clonoSEQ® Assay

The Royal Marsden NHS Foundation Trust · Transparency notice on Find a Tender

Tender information last checkedLast checked 30 Sept 2026, 14:34.

Opportunity overview

The procurement of a next-generation sequencing (NGS)–based test assay designed for the detection and monitoring of minimal residual disease (MRD) in patients with certain haematologic malignancies, such as multiple myeloma, acute lymphoblastic leukaemia (ALL), and chronic lymphocytic leukaemia (CLL). The required goods and services include: • Provision of assay kits and reagents suitable for the intended patient population. • Use of a software platform for analysis and reporting of results. • Training and technical support for laboratory and clinical staff to ensure accurate sample processing, data interpretation, and integration into clinical workflows. • Ongoing technical support, maintenance, and updates for both hardware (if applicable) and software components. • Delivery of consumables and reagents on a schedule that aligns with clinical demand, ensuring continuity of patient testing. • Compliance with all relevant regulatory standards (e.g., CE-IVD, UKCA marking) and data protection requirements for patient information. • Optional: Integration with existing laboratory information management systems (LIMS) and electronic health records (EHR), if required. • MRD sensitivity threshold of 10-5 or lower • Must work on DNA • Performance data must be supported by evidence generated in relevant disease specific Clinical Trials • Recognised technology included in clinical guidelines • Ability to track clonal evolution

Awarded to

Amounts belong to published awards or contracts. Where several suppliers share one value, it is labelled as shared and is not a supplier-specific allocation.

Adaptive Biotechnologies Corporation

No match
Published award value
£1.2m
Awarded
22 Dec 2025
Award ID
1
Status
pending
Identifier
GB-PPON PBYH-2894-GJWD
Location
Seattle, US, WA 98109, United States

Classification

No classification was supplied.

Lots

  • Lot 1Value not stated

Documents and notices

Published notice details

Additional information from the published procurement release. Fields appear only when supplied by the source; check the original notice and tender documents before acting.

Scope, procedure and submissions

Id
ocds-h6vhtk-05fb40
Status
complete
Published risks
Delayed supply
Procurement Method
direct
Procurement Method Details
Direct award
Why this procedure was chosen
The supplier owns the IP for this assay. The unique factors are detailed below: Unique Capabilities: • Sensitivity: clonoSEQ can detect MRD down to one cancer cell among a million healthy cells, deeper than flow cytometry or PCR. This level of sensitivity is critical for accurately assessing MRD in patients for both depth of response and early relapse detection. • Standardization: clonoSEQ is a sole-source test. All reagents, materials, and equipment are needed to perform the assay. • FDA Approval: clonoSEQ is the first and only FDA-cleared assay for MRD detection ALL, CLL or MM. • Comprehensive Data Analysis: The assay includes sophisticated bioinformatics tools that offer detailed insights into clonal evolution and disease progression, which are not available with other MRD testing methods, resulting in a tracking report of disease burden over time. • Clinical Guidelines: NGS MRD assessment is included in clinical guidelines for ALL, CLL, DLBCL, and multiple myeloma. Monitoring MRD is crucial for assessing the treatment effectiveness and early detection of relapse in patients with lymphoid malignancies, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), diffuse large b-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and multiple myeloma (MM). Traditional methods, such as flow cytometry and polymerase chain reaction (PCR), lack the sensitivity and standardisation required for consistent and deep MRD detection across different laboratories and clinical settings. The clonoSEQ Assay was developed by Adaptive Biotechnologies in accordance with CLIA/College of American Pathologists (CAP) requirements. Adaptive Biotechnologies is a single-source provider of the clonoSEQ Assay and therefore is uniquely positioned to meet the MRD detection needs for patients.

Legal basis

Id
2023/54
Scheme
UKPGA

Procedure reasons

Entry 1
Id
singleSuppliersIntellectualPropertyExclusiveRights

Lots and requirements

Entry 1
Id
1
Status
complete

Suitability

Sme
Yes
Vcse
Yes

Published documents

Entry 1
Id
conflictOfInterest
Description
Not published
Document Type
conflictOfInterest

Buyer, suppliers and contacts

Organisation 1
Id
GB-PPON-PXLT-9823-WVCY
Name
The Royal Marsden NHS Foundation Trust

Roles

buyer

Address

Region
UKI33
Country
GB
Locality
London
Postal Code
SW3 6JJ
Country Name
United Kingdom
Street Address
Fulham Road

Details

Classifications

Entry 1
Id
publicAuthorityCentralGovernment
Scheme
UK_CA_TYPE
Description
Public authority - central government

Identifier

Id
PXLT-9823-WVCY
Scheme
GB-PPON

Contact

Name
Gemma Fahey
Organisation 2
Id
GB-PPON-PJXH-4297-MQQW
Name
Central London Community Healthcare NHS Trust
Role Details
CLCH host a collaborative, outsourced procurement service - North West London Procurement Services.

Roles

procuringEntity

Address

Region
UKI32
Country
GB
Locality
London
Postal Code
NW1 5JD
Country Name
United Kingdom
Street Address
Ground Floor, 15 Marylebone Road

Details

Identifier

Id
PJXH-4297-MQQW
Scheme
GB-PPON

Contact

Name
Gemma Fahey
Organisation 3
Id
GB-PPON-PBYH-2894-GJWD
Name
Adaptive Biotechnologies Corporation

Roles

supplier

Address

Region
US
Country
US
Locality
Seattle
Postal Code
WA 98109
Country Name
United States
Street Address
1165 Eastlake Ave E, Seattle, United States

Details

Vcse
No
Scale
sme
Sheltered Workshop
No
Public Service Mission Organization
No

Identifier

Id
PBYH-2894-GJWD
Scheme
GB-PPON

Contact

Award information

Award 1
Id
1
Date
22 Dec 2025, 00:00
Title
RMH clonoSEQ® Assay
Status
pending
Above Threshold
Yes
Main Procurement Category
goods

Items

Item 1
Id
1
Related Lot
1

Delivery locations

Entry 1
Region
UKI
Country
GB
Country Name
United Kingdom
Entry 2
Region
UKI
Country
GB
Country Name
United Kingdom

Additional Classifications

Entry 1
Id
33696500
Scheme
CPV
Description
Laboratory reagents

Value

Amount
1,158,208.33
Currency
GBP
Including VAT
1,389,850

Documents

Entry 1
Id
085271-2025
Format
text/html
Notice Type
UK5
Description
Transparency notice on Find a Tender
Document Type
awardNotice
Published
22 Dec 2025, 10:38
Entry 2
Id
086403-2025
Format
text/html
Notice Type
UK6
Description
Contract award notice on Find a Tender
Document Type
awardNotice
Published
30 Dec 2025, 11:11

Suppliers

Supplier 1
Id
GB-PPON-PBYH-2894-GJWD
Name
Adaptive Biotechnologies Corporation

Milestones

Entry 1
Id
1
Type
futureSignatureDate
Status
scheduled
Due
15 Jan 2026, 23:59

Related lots

1

Contract period

Ends
19 Jan 2031, 23:59
Starts
20 Jan 2026, 00:00

Standstill Period

Ends
12 Jan 2026, 23:59

Recorded locations

  • Buyer location · London · UKI33 · SW3 6JJ · United Kingdom

Notice and amendment history

1 published notice version reviewed by ProcuraAxis.

1 VERSION
  1. ocds-h6vhtk-05fb40-2025-12-30T11:11:50ZTransparency notice on Find a Tender ·